No Data
No Data
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
Achilles Therapeutics Announces Publication of Nature Cancer 'Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction
LONDON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid
Achilles Therapeutics Cut to Underperform From Buy by B of A Securities
Achilles Therapeutics Cut to Underperform From Buy by B of A Securities
B of A Securities Downgrades Achilles Therapeutics to Underperform, Lowers Price Target to $0.5
B of A Securities analyst Tazeen Ahmad downgrades Achilles Therapeutics (NASDAQ:ACHL) from Buy to Underperform and lowers the price target from $7 to $0.5.
Achilles Therapeutics Cash And Cash Equivalents As Of Sept. 30 Were $140.1M
Achilles Therapeutics Cash And Cash Equivalents As Of Sept. 30 Were $140.1M
No Data